Portfolio company Respira Therapeutics entered an option agreement granting Gossamer Bio the right to acquire it and its lead pulmonary hypertension candidate, RT234.
Respira is developing next-generation cardiopulmonary disease-targeted inhalation products, focusing on advanced particle engineering and proprietary device technologies to enhance drug delivery to the lung periphery
Respira is developing next-generation cardiopulmonary disease-targeted inhalation products, focusing on advanced particle engineering and proprietary device technologies to enhance drug delivery to the lung periphery.